Mathilde Cabart
Mathilde Cabart is an expert in Oncology at Institut Bergonié (France). Mathilde Cabart has authored 36 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 229 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Geriatrics - Pulmonology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2015 - 2026
Number : 36
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial. PMID 42905748 — neoplasms, carcinoma, non-small-cell lung, therapeutics, tissues, plasma | Clin Cancer Res | 2026 | 0 |
| Important aspects of care and priorities of older patients with cancer: The PRIORITY multicenter cohort study. PMID 41233219 — treatment outcome, neoplasms, cohort studies, life expectancy, physicians, therapeutics | J Geriatr Oncol | 2025 | 0 |
| PFMG2025-integrating genomic medicine into the national healthcare system in France. PMID 40093400 — genomic medicine | Lancet Reg Health Eur | 2025 | 57 |
| Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. PMID 39591972 — cells, genes, lung, lymphocytes, biological science disciplines, neoplasms, adenocarcinoma, carcinoma, non-small-cell lung, adenocarcinoma of lung, biomarkers, immunotherapy, immune checkpoint inhibitors, cell death, tumor microenvironment | Cell Rep Med | 2024 | 5 |
| Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database. PMID 39068144 — cells, lung, smokers, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, aged, lung neoplasms, small cell lung carcinoma, therapeutics, prognosis, chemotherapy | J Geriatr Oncol | 2024 | 1 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator s Choice in Chemotherapy na ve Metastatic Castration resistant Prostate Cancer 2025-520555-89-00 — neoplasms, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, chemotherapy | Phase 3 | Recruiting | 2025 |
| Impact of a Physical Activity Program to Reduce Long term Cancer related Fatigue in Metastatic Testicular Germ Cell Tumor Patients NCT05588700 — exercise, cells, fitness centers, testicular neoplasms, neoplasms, drug therapy, fatigue, germ cells, therapeutics, environment, gastrointestinal microbiome, microbiota, chemotherapy, lifestyle and wellness apps, men | N/A | Recruiting | 2025 |
LeadR Networks
Main global connection map